Dr. Larry L. Kestin

  • MD, FACR
  • Radiation Oncologist
  • Spoken languages English

Overview

Larry L. Kestin, MD, FACR, FASTRO has authored over 100 peerreviewed journal publications and over 200 abstracts and several book chapters. He is a radiation oncology written and oral boards examiner for the American Board of Radiology and Chair of the Lung/Sarcoma section. He is a member of the NCI Thoracic Malignancy Steering Committee and has been a member of multiple ASTRO Committees. He has held academic appointments as a full professor at Oakland University and UCLA and was Program Director for the Department of Radiation Oncology at William Beaumont Hospital. He is actively involved in clinical research and has served as Principal Investigator for many local as well as national clinical trials.

Career Positions

Current position(s)

  • GenesisCare - Medical Director, Michigan Region, Farmington Hills, MI

Past position(s)

  • GenesisCare - National Director of Thoracic and Lung Services, Farmington Hills, MI
  • Oakland University William Beaumont School of Medicine - Full Professor, Royal Oak, MI
  • Oakland Community College - Full Professor, Bloomfield Hills, MI

Education

Universities

  • University of Missouri, BS, Computer Science, Columbia, MO
  • University of Kansas School of Medicine, Kansas City, KS

Residencies

  • William Beaumont Hospital, Radiation Oncology, Chief Resident, Royal Oak, MI

Internships

  • William Beaumont Hospital, Rotating Program, Royal Oak, MI

Expertise And Interests

Interests

  • Lung / Thoracic, Lymphoma, Sarcoma, Prostate, GenitoUrinary Malignancies, Breast

Accomplishments

Awards and honors

  • Best Doctors in America &

Publications

  • Stereotactic image-guided lung radiotherapy (SBRT) for clinical early-stage NSCLC: A long-term report from a multi-institutional database of patients treated with or without a pathologic diagnosis.
  • Cardiac Dose in Locally Advanced Lung Cancer: Results from a Statewide Consortium.
  • In Vivo Verification and Daily and Cumulative Dose Recalculation for Helical Tomotherapy: Multi Center Validation Based on Greater than 150,000 Daily Fractions Delivered
Expand Publications
View 1 more

Presentations

Z091420168

E. Arrojo, E. Fernandez, L. Kestin, A. Martinez, 2016, ACRO

View Presentation

Z083120151

Martinez A, Olivera G, Ghilezan M, Forman J, Kestin L, Finkelstein S, Mo X, Key S, Mantz C, Fernandez E, Galmarini D, et al., 2015, ASTRO Annual Meeting

View Presentation

Z061520151

Kestin L, Fernandez E, Mantz C, Olivera G, Mo X, Key S, Finkelstein SE, Martinez A, Galmarini D., 2015, ASTRO Annual Meeting

View Presentation
Expand Presentations
View 1 more

Clinical studies

Primary Objective The primary goal of this study is to determine whether, in men with postprostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.

View Study

Larry Kestin's Reviews

Overall

based on 81 Ratings 15 Comments

2020

The staff is first rate and I can think of nothing that could improve the experience

2020

I don't know what else you could have done. Everything was cool. I was happy and I don't know what else to say.

2020

Can't think of anything.

2020

Nothing, very happy with my experience with 21st Century Oncology

Read More

Ratings and Comments Powered by NRC Health